| COMPANY |
Twist Bioscience Corporation |
| COURT |
United States District Court for the Northern District of California |
| CASE NUMBER |
22-cv-08168 |
| JUDGE |
The Hon. Edward John Davila |
| CLASS PERIOD |
December 13, 2019, and November 14, 2022 |
| SECURITY TYPE |
Common Stock |
Case Background:
A class action lawsuit was filed on behalf of those who purchased or acquired Twist Bioscience Corporation ("Twist") (NASDAQ: TWST) common stock between December 13, 2019 and November 14, 2022, both dates inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about Twist’s business and operations. Specifically, as alleged in the Scorpion Report, Defendants overstated the commercial viability of Twist’s synthetic DNA manufacturing technology while engaging in accounting fraud and using unsustainable pricing to inflate the company’s true financial condition and prospects.
Current Status of Case:
On December 6, 2023, Defendants filed a Motion to Dismiss which is currently being briefed by the parties. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.